FDA targets GLP-1 weight loss drugs: Regulatory shift prioritizes Big Pharma over compounding pharmacies amid global supply disparities
Original framing: “STAT+: FDA wants to exclude weight loss drugs from a compounding list” — STAT News
The FDA's move reflects a long-standing pattern of pharmaceutical monopolization, where patent laws and regulatory exclusivity have historically concentrated power in the hands of a few corporations. This trend dates back to the 1980s Bayh-Dole Act and the Hatch-Waxman Act, which incentivized patenting and market exclusivity for drugs, often at the expense of affordability and accessibility. The current policy echoes past instances where compounding pharmacies were sidelined to protect corporate profits, such as during the HIV/AIDS crisis when generic drugs were similarly restricted.
The FDA's decision to exclude GLP-1 weight loss drugs from compounding lists is a microcosm of a broader systemic issue: the prioritization of corporate profit over public health.
This policy, driven by the lobbying power of Novo Nordisk and Eli Lilly, reflects a historical pattern of pharmaceutical monopolization that dates back to the 1980s, when patent laws were rewritten to favor Big Pharma. The move disproportionately harms marginalized communities, including low-income patients, people of color, and rural residents, who rely on affordable alternatives like compounded medications. It also undermines culturally embedded healthcare systems, particularly in the Global South, where traditional and compounding pharmacies have long provided accessible care. To address this, systemic solutions must include decoupling drug pricing from patent monopolies, expanding compounding pharmacy access, and integrating traditional medicine into mainstream healthcare. Only by challenging the hegemony of corporate-controlled pharmaceuticals can we ensure equitable access to essential medicines for all.